**Patient Discharge Summary**

**Patient Information**

* Name: John Doe
* Date of Birth: February 12, 1965
* Admission Date: March 10, 2023
* Hospital Stay: 10 days

**Chief Complaint and Reason for Admission**

John Doe was admitted to the endocrinology unit on March 10, 2023, with a chief complaint of increased thirst and urination over the past 6 weeks. He had a history of obesity and was diagnosed with hypertension and hyperlipidemia 5 years ago. His fasting plasma glucose (FPG) level was 240 mg/dL (13.3 mmol/L) on March 5, 2023, which was significantly elevated. He was referred to the endocrinology unit for further evaluation and management of his hyperglycemia.

**Diagnostic Workup**

Upon admission, John Doe underwent a comprehensive diagnostic workup, which included:

* Fasting plasma glucose (FPG) level: 240 mg/dL (13.3 mmol/L)
* Glycosylated hemoglobin (HbA1C) level: 9.5%
* Oral glucose tolerance testing (OGTT): Not performed due to patient's intolerance to glucose
* Random glucose value: 220 mg/dL (12.2 mmol/L)

The results of the diagnostic workup confirmed the diagnosis of type 2 diabetes mellitus.

**Treatment and Management**

John Doe was treated with a multidisciplinary approach, including dietary recommendations, physical activity counseling, and pharmacological therapy.

* Dietary recommendations: Individualized diet plan focusing on whole foods, high-quality carbohydrates, and portion control. He was advised to limit his daily carbohydrate intake to 45-50% of total daily calories.
* Physical activity: Encouraged to engage in at least 150 minutes of moderate-intensity aerobic exercise per week, with adjustments for hypoglycemia risk.
* Pharmacological therapy:
	+ Metformin: 500 mg twice daily, started on March 12, 2023
	+ Semaglutide: 2.4 mg once weekly, started on March 15, 2023

**Medication Adherence and Monitoring**

John Doe was advised to monitor his blood glucose levels at home using a glucometer and to adjust his insulin doses based on his blood glucose levels and carbohydrate intake. He was also advised to monitor for signs and symptoms of hypoglycemia and hyperglycemia.

**Patient Education and Counseling**

John Doe received comprehensive education and counseling on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and the importance of regular monitoring and medication adherence. He was also advised to adjust his insulin doses based on his blood glucose levels and carbohydrate intake.

**Discharge Instructions**

Upon discharge, John Doe was instructed to:

* Continue his metformin and semaglutide therapy as prescribed
* Monitor his blood glucose levels at home and adjust his insulin doses based on his blood glucose levels and carbohydrate intake
* Report any signs or symptoms of hypoglycemia or hyperglycemia to his healthcare provider
* Attend regular follow-up appointments with his healthcare provider to monitor his blood glucose control and adjust his therapy as necessary
* Engage in regular physical activity and maintain a healthy diet

**Follow-up and Future Plans**

John Doe is scheduled to return to the endocrinology unit on April 15, 2023, for a follow-up appointment to monitor his blood glucose control and adjust his therapy as necessary. He will also undergo regular monitoring for diabetic complications, including foot and funduscopic examinations, urine testing for albuminuria, and measurement of serum creatinine and lipid profile.

**Conclusion**

John Doe was diagnosed with type 2 diabetes mellitus and was treated with a multidisciplinary approach, including dietary recommendations, physical activity counseling, and pharmacological therapy. He was advised to monitor his blood glucose levels at home and adjust his insulin doses based on his blood glucose levels and carbohydrate intake. He will require regular follow-up appointments to monitor his blood glucose control and adjust his therapy as necessary.